Xiaobo Wang

Has grant

Assistant Professor

Columbia University Irving Medical Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Xiaobo Wang is an Assistant Professor at Irving Medical Center, Columbia University, USA. His research primarily focuses on liver diseases, particularly the molecular mechanisms underlying metabolic dysfunction-associated steatohepatitis (MASH) and its progression to fibrosis and hepatocellular carcinoma. Recent articles authored by Dr. Wang explore pathways related to efferocytosis, macrophage function, and genetic risk factors influencing liver pathology.

Recent Grants

Grant: Close

Liver Schorlar Award

Open Date: 2018-07-01

Close Date: 2021-06-01

Grant: Close

American Heart Association Postdoc Fellowship

Open Date: 2012-07-01

Close Date: 2015-01-01

Articles (17)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (6)

Ira Tabas

Professor

Columbia University Irving Medical Center

UNITED STATES

View details

Alberto Bartolomé

Instituto de Investigaciones Biomédicas Alberto Sols

SPAIN

View details

Utpal Pajvani

UNITED STATES

View details

Hanrui Zhang

Assistant Professor

Columbia University Irving Medical Center

UNITED STATES

View details

Yoshinobu Saito

Assistant Professor

Osaka University

JAPAN

View details

Jinjun Shi

Associate Professor

Brigham and Women's Hospital

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Xiaobo Wang

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (17)

A non-apoptotic caspase-8–meteorin pathway in hepatocytes promotes MASH fibrosis

Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction-associated steatohepatitis

Low MBOAT7 expression, a genetic risk for MASH, promotes a profibrotic pathway involving hepatocyte TAZ upregulation

Publisher Correction: Efferocytosis drives a tryptophan metabolism pathway in macrophages to promote tissue resolution

Efferocytosis drives a tryptophan metabolism pathway in macrophages to promote tissue resolution

Molecular mechanisms in MASLD/MASH-related HCC

Efferocytosis in liver disease

CD47-SIRPα axis blockade in NASH promotes necroptotic hepatocyte clearance by liver macrophages and decreases hepatic fibrosis

Macrophages use apoptotic cell-derived methionine and DNMT3A during efferocytosis to promote tissue resolution

Challenges and opportunities in nonalcoholic steatohepatitis

TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis

TOX4, an insulin receptor-independent regulator of hepatic glucose production, is activated in diabetic liver

Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis

Deficiency of macrophage PHACTR1 impairs efferocytosis and promotes atherosclerotic plaque necrosis

Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis

Interacting hepatic PAI-1/tPA gene regulatory pathways influence impaired fibrinolysis severity in obesity

Liver cholesterol matters

Collaborators (6)

Ira Tabas

Alberto Bartolomé

Utpal Pajvani

Hanrui Zhang

Yoshinobu Saito

Jinjun Shi

Make your next move.